Research and Developments

Page 3 of 1812345...10...Last »

May 20, 2016

Visual Impairment and Blindness in U.S. May Double by 2050

Posted in: Latest News, Research and Developments

The findings of a recent study suggest that there is a need for increased screening and interventions to identify and address treatable causes of vision loss. With the youngest of the baby boomers hitting 65 by 2029, the number of people with visual impairment or blindness in the United States is expected to double to
read more »

May 5, 2016

OPT-302 Enters Phase 2A Trials for Wet AMD

Posted in: Latest News, Research and Developments

Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has randomized and dosed the first patient in the Phase 2A dose expansion clinical trial of OPT-302 for wet AMD. OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule, that blocks the activity of two
read more »

April 14, 2016

Smoking and AMD—Are E-Cigarettes the Answer?

Posted in: Health and Nutrition, Latest News, Research and Developments

by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood
read more »

March 6, 2016

Experimental Gene Therapies Still Raising Hopes

Posted in: Latest News, Research and Developments

Wills Eye Hospital has announced that it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. A product called GS010 (GenSight Biologics), can be injected right into the eye and, in a sense, “re-wire” or lower the patient’s risk for getting the disease. The patient has
read more »

February 27, 2016

Future Sustained Drug Delivery Methods for Choroidal Neovascularization

Posted in: Latest News, Research and Developments

During the American Academy of Ophthalmology’s Retina Subspecialty Day in 2015, Peter K. Kaiser, MD, described six alternative methods being looked at for delivery of anti-VEGF drugs into the retinas of individuals experiencing choroidal neovascularization (CNV). Periodic intraocular injections are currently the only procedure for halting damaging blood vessel growth and leakage. Injections are expensive, time-consuming, and burdensome on the patients, so
read more »

February 15, 2016

New Combination Therapy Treats Retinal Damage in Diabetics

Posted in: Latest News, Research and Developments

Aerpio Therapeutics, Inc. has announced promising results from their “TIME-2” study of  AKB-9778 as a treatment for diabetic retinopathy (DR). AKB-9778 alone and in combination with Lucentis® (ranibizumab) improved underlying retinopathy by 10.0%, and 11.4% compared to 8.8% of patients receiving Lucentis® alone. The clinical findings were presented by Pravin U. Dugel, M.D., at the
read more »

February 10, 2016

AVA-101 May Extend Time Between Wet AMD Treatments

Posted in: Latest News, Research and Developments

In 2014, Avalanche Biotechnologies postulated that a single injection of a new gene therapy treatment could possibly stop blood vessel growth and leakage in the wet form of Age-Related Macular Degeneration (AMD) for several years. A single injection of a drug called AVA-101 (aka sFlt-1) could create a kind of biofactory that continuously secretes a therapeutic protein
read more »

February 5, 2016

High Dose Statins May Be Effective In Treating Dry AMD

Posted in: Latest News, Research and Developments

Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have found that high doses of statins (cholesterol-lowering medications) can effectively reduce the number of soft drusen deposits in retinas of people with dry age-related macular degeneration (dAMD). The findings from their phase I/II clinical trial were published in the recent issue of
read more »

February 3, 2016

Accessible Driving Is On The Horizon

Posted in: Latest News, Research and Developments

by Dan Roberts A couple of changes are on the horizon which may allow visually impaired people to regain or maintain the pleasure of piloting their own private vehicles whenever and wherever they choose. The most immediate change could come from relaxation of the minimum visual acuity requirements, made possible in part by the development of bioptic
read more »

January 27, 2016

New Drug Under Study for Dry MD

Posted in: Latest News, Research and Developments

Ophthotech Corporation has announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (MD).  Zimura® is an inhibitor of complement factor C5, a central component of the complement cascade believed to be involved in the development of AMD. The Company has also recently
read more »

Page 3 of 1812345...10...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann